Rankings / Metabolic Health

Petrelintide (ZP8396)

Metabolic Health · Amylin analog

Tier C+

Reviewed by Read Off Label · Last reviewed · How we grade

amylininjectable-peptideinvestigationalweight-loss
5.7 / 10
Tier C+
Ev 6 Bn 6.5 Sf 5

Bottom line

Read Off Label grades Petrelintide (ZP8396) as C+ (5.7/10) based on moderate evidence, med-high benefit magnitude, and a med-risk safety profile.

Roche/Zealand Pharma long-acting amylin analog.

Typical use: SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2 — Investigational.

What this is

Roche/Zealand Pharma long-acting amylin analog. Phase 2 ZUPREME-1 (n=485; US/Poland/Romania) presented at ADA 2026: up to 10.7% body-weight loss vs 1.7% placebo at week 42 (p<0.001); 88-98% reached target maintenance dose; nausea 19.6% (>75% mild), only 1.5% discontinued for GI events. Amylin monotherapy positioned as a better-tolerated alternative or combination partner to GLP-1 agonists. Phase 3 for chronic weight management planned H2 2026. Industry-sponsored; conference data, peer-reviewed publication pending.

Mechanism

Long-acting amylin analog given once-weekly subcutaneously; promotes satiety and restores leptin sensitivity to curb food intake — an amylin-monotherapy approach to weight loss distinct from GLP-1 (incretin) agonists

Dose & route

SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2

Citations

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Petrelintide (ZP8396) work?
Read Off Label rates the evidence for Petrelintide (ZP8396) as Moderate and the benefit magnitude as med-high, producing an overall grade of C+ (5.7/10). Roche/Zealand Pharma long-acting amylin analog.
Is Petrelintide (ZP8396) safe?
Petrelintide (ZP8396) has a med risk profile in published human data. Legal status: Investigational (Phase 3 planned H2 2026). This is not medical advice — see the disclaimer.
What is the typical dose for Petrelintide (ZP8396)?
SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2
How does Petrelintide (ZP8396) work?
Long-acting amylin analog given once-weekly subcutaneously; promotes satiety and restores leptin sensitivity to curb food intake — an amylin-monotherapy approach to weight loss distinct from GLP-1 (incretin) agonists

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.